Steady progress for UK healthcare M&A in H1, report finds
Amid shifting global dynamics, continued resilience in UK healthcare M&A deal activity is expected in H2 2025, forecasting predicts.
List view / Grid view
Amid shifting global dynamics, continued resilience in UK healthcare M&A deal activity is expected in H2 2025, forecasting predicts.
In this article, Patrice Navarro, Tech Partner (Healthcare & Life Sciences Sector), Clifford Chance, discusses the AI Act and the related compliance considerations for pharmaceutical companies in the EU.
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.
The new deal could support innovation of next-generation combination vaccines to protect older adults against multiple respiratory viruses.
The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease.
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.
The acquisition aligns with one of Sanofi’s four strategic disease areas and supports the company in utilising its immunology expertise to address areas of unmet need.
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
The merger deal between Novartis AG and Regulus Therapeutics is expected to push forward development of a potential first-in-class kidney disease drug.
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
The proposed acquisition, worth nearly $300 million, could help to advance cell therapy in the oncology field.
The potentially multi-billion-dollar deal strengths Novartis’ late-stage pipeline for cardiovascular therapies, signalling advancement of novel treatments for heart disease.
For a strong 2025, dealmaking should be central to the life sciences strategy, says EY’s annual M&A report.